July 30, 2020
Otsuka Pharmaceutical said on July 29 that it has filed a new drug application in Japan for its anti-CGRP (calcitonin gene-related peptide) monoclonal antibody fremanezumab (TEV-48125) for the preventive treatment of migraines. The company obtained exclusive rights to develop and...read more